Rossari Biotech: Market share gain in textile chemicals is comforting

In the longer term, what we like about Rossari Biotech is that it's led by technocrats with strong domain knowledge, which in turn has helped in superior execution of capex projects in the past and diversification into new end-markets

Interview | Sky is the limit for the growth of our core business, says Sunil Chari, MD of Rossari Biotech

Rossari Biotech is confident of doubling sales in 3-4 years, and the home and personal care category is expected to comprise over half of the company's revenues in the coming quarters, says its co-founder and MD

Rossari Standalone September 2020 Net Sales at Rs 173.71 crore, up 15.55% Y-o-Y

Rossari Standalone September 2020 Net Sales at Rs 173.71 crore, up 15.55% Y-o-Y

Expect 15% growth in FY21: Rossari Biotech's Sunil Chari

Rossari Biotech reported profit after tax (PAT) of Rs 20.7 crore in Q2FY21, higher than Rs 17.7 crore reported in the same period last year.

Rossari Biotech: Sharp recovery in legacy business adds to investment case

Rossari Biotech's growth is likely to be led by performance chemicals business in the medium term

Speciality Chemicals stocks rally 300-1,000% in last 5 years: Is there any juice left?

Smart investors would look for dark horses in this segment which will do the ‘catch-up’ over the next few quarters.

Rossari Biotech: What next after a stellar post-listing run?

While Rossari Biotech has proven to be a strong beneficiary of the opportunity for chemical cleanliness solutions, its valuation is well ahead of fundamentals in our view

3 Point Analysis | Rossari Biotech's stellar listing: What should investors do now?

The stock opened with a premium of Rs 245, or 58 percent, on the BSE against its issue price of Rs 425 per share, and rose to Rs 710 intraday, i.e. 67.1 percent higher

Goldman Sachs ups stake in Rossari Biotech, Norges Bank raises holding in IndiaMART

Plutus Wealth Management bought 4,77,637 shares in the company at Rs 669.25 per share.

Rossari Biotech hits upper circuit intraday, closes Day 1 with 75% gains at Rs 742.35

Rossari Biotech is among top 11 companies that showed remarkable performance, listing at a premium of over 50 percent in last five years.

Rossari Biotech's bumper listing: what should investors do with the stock now?

Astha Jain, Senior Research Analyst at Hem Securities also said if the stock lists at more than 40 percent premium then investors are advised to book partial profit.

Rossari Biotech debuts at Rs 670 with 58% premium over IPO price

The listing premium was much higher than the grey market premium (of around Rs 160-180 per share) as well as analysts' expectations of Rs 130-175 per share.

Rossari Biotech to debut today: Here's what to expect from the listing

Rossari Biotech's public issue that consisted a fresh issue of Rs 50 crore and offer for sale of 1.05 crore equity shares by promoters closed with 79.37 times subscription on July 15

Rossari Biotech IPO: Check the details of share allotment here

The equity shares received in the allotment are expected to be credited to DP accounts on July 22 and the listing of shares is likely to take place on July 23.

Buy on dips, sell on rise best strategy till Nifty touches 11,300-11,500: Sumit Bilgaiyan

As FII inflows continue to remain strong, the liquidity remains healthy and hence sharper correction without a specific event trigger on domestic/global seems unlikely.

Subscribe to Rossari Biotech: Ajcon Research

Ajcon Research Rossari Biotech Started in CY03 as “Rossari Lab tech”, a partnership firm, Rossari was converted to Company in CY09 by Mr. Edward Menezes and Mr. Sunil Chari.

Rossari Biotech's Rs 496-crore IPO subscribed 79 times so far on last day

The public issue consists of a fresh issue of Rs 50 crore and an offer for sale of 1.05 crore equity shares by its promoters Edward Menezes and Sunil Chari.

Rossari Biotech IPO subscribed 3 times on Day 2 amid retail, QIB interest

In past 3 years (FY17-FY20), company has delivered stupendous growth on revenue, EBITDA and net profit level, which grew at a CAGR of 42 percent, 57 percent and 60 percent respectively.

Subscribe to Rossari Biotech: Emkay Global Financial

Emkay Global Financial Rossari Biotech is planning to raise ~Rs4.95bn through a mix of fresh issue (Rs500mn, 1.17mn shares) combined with Offer for Sale (OFS) route (~Rs4.45bn, 10.5mn shares), to the public.

Subscribe to Rossari Biotech: Motilal Oswal

Motilal Oswal Hence, investors can Subscribe the IPO from a long term perspective.

Subscribe to Rossari Biotech: Ventura Securities

Ventura Securities Rossari Biotech (Rossari) is one of the leading specialty chemicals manufacturing company in India, catering to various customer needs across FMCG, apparel, and poultry and animal feed industries.

Subscribe to Rossari Biotech: Mehta Equities

Mehta Equities has come out with its report on Rossari Biotech. The research firm has recommended to "Subscribe'' the IPO in its research report as on July 10, 2020

Subscribe to Rossari Biotech: Arihant Capital

Arihant Capital has come out with its report on Rossari Biotech. The research firm has recommended to "Subscribe'' the IPO in its research report as on July 10, 2020

Subscribe to Rossari Biotech: Hem Securities

Hem Securities has come out with its report on Rossari Biotech. The research firm has recommended to "Subscribe'' the IPO in its research report as on July 10, 2020